Daniel Judge to Prealbumin
This is a "connection" page, showing publications Daniel Judge has written about Prealbumin.
Connection Strength
3.312
-
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 06; 34(3):357-370.
Score: 0.698
-
Positive family history decreases diagnosis time by over 200. Amyloid. 2019; 26(sup1):17.
Score: 0.632
-
Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Amyloid. 2017 Jun; 24(2):92-95.
Score: 0.564
-
ATTR Epidemiology, Genetics, and Prognostic Factors. Methodist Debakey Cardiovasc J. 2022; 18(2):17-26.
Score: 0.197
-
Wild-Type Transthyretin Cardiac Amyloidosis Is Associated with Increased Antecedent Physical Activity. J Cardiovasc Transl Res. 2022 08; 15(4):689-691.
Score: 0.196
-
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13; 379(11):1007-1016.
Score: 0.154
-
Untangling Wild-Type Transthyretin?Amyloidosis. J Am Coll Cardiol. 2016 09 06; 68(10):1021-3.
Score: 0.135
-
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016 07 12; 68(2):161-72.
Score: 0.133
-
Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015 May; 8(3):519-26.
Score: 0.122
-
Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015 Mar; 8(2):117-27.
Score: 0.121
-
Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013 Dec; 6(6):1011-20.
Score: 0.110
-
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012 Aug; 164(2):222-228.e1.
Score: 0.101
-
Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. ESC Heart Fail. 2021 10; 8(5):3875-3884.
Score: 0.047
-
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021 02; 23(2):277-285.
Score: 0.045
-
Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Ann Neurol. 2017 Jul; 82(1):44-56.
Score: 0.036
-
Familial amyloid cardiomyopathy due to TTR mutations: an underdiagnosed cause of restrictive cardiomyopathy [corrected]. J Card Fail. 2009 Jun; 15(5):464.
Score: 0.020